Cancer Monoclonal Antibody Therapy: Mechanisms, Approved Drugs & Emerging Trends

Cancer monoclonal antibody therapy has become the largest single class of oncology therapeutics, with more than 100 biologics approved by the FDA and annual global sales exceeding $150 billion. From the first therapeutic antibody rituximab in 1997 to the latest bispecific T-cell engagers and antibody-drug conjugates, monoclonal antibodies (mAbs) now cover virtually every major cancer antigen and mechanism of immune evasion. This guide explains how they work, which drugs are approved and for what, and how next-generation formats are reshaping the field.

What Are Monoclonal Antibodies?

Monoclonal antibodies are monospecific immunoglobulins produced by a single B-cell clone — every molecule in the batch recognizes the same epitope with identical affinity and isotype. The clinical antibody portfolio spans four engineering generations:

• Murine (suffix -omab): derived entirely from mouse; highly immunogenic in humans — largely replaced clinically.
• Chimeric (suffix -ximab): mouse variable regions fused to human constant regions (e.g., rituximab, cetuximab); ~65% human sequence.
• Humanized (suffix -zumab): only the complementarity-determining regions (CDRs) remain murine (e.g., trastuzumab, bevacizumab); ~95% human.
• Fully human (suffix -umab): generated via phage display or transgenic mice (e.g., panitumumab, ipilimumab, pembrolizumab); 100% human sequence, lowest immunogenicity.

Structurally, the IgG1 isotype dominates oncology. The Fab arms bind the target antigen; the Fc region engages Fcγ receptors on immune effector cells and complement component C1q, enabling antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-dependent cellular phagocytosis (ADCP). Rituximab's approval in 1997 for CD20-positive B-cell non-Hodgkin lymphoma — drawing on the foundational hybridoma technology described by Köhler and Milstein in 1975 (Köhler & Milstein, Nature 1975) — launched the modern mAb era in oncology.

Mechanisms of Action of Cancer Monoclonal Antibody Therapy

Cancer monoclonal antibody therapy operates through four mechanistically distinct strategies that are sometimes combined in a single drug:

1. Direct Tumor Killing via Effector Functions

Naked IgG1 mAbs binding tumor-surface antigens recruit NK cells (ADCC via FcγRIIIA/CD16a), activate complement (CDC), and promote macrophage phagocytosis (ADCP). Rituximab (anti-CD20) and trastuzumab (anti-HER2) derive significant clinical benefit from ADCC in addition to their direct antiproliferative effects. Fc-engineering approaches — such as afucosylation or S239D/I332E substitutions — enhance FcγRIIIA binding and boost ADCC activity (Adams & Weiner, Nat Biotechnol 2005).

2. Growth Factor Receptor Blockade

Antibodies targeting receptor tyrosine kinases block ligand binding, prevent receptor dimerization, and trigger receptor internalization and degradation. Trastuzumab sterically blocks HER2 dimerization and recruits the E3 ligase c-Cbl for receptor downregulation. Cetuximab and panitumumab compete with EGF for EGFR binding, halting the RAS–RAF–MEK–ERK and PI3K–AKT–mTOR proliferation cascades. Bevacizumab neutralizes circulating VEGF-A, collapsing the tumor neovasculature and starving tumor tissue of oxygen and nutrients.

3. Immune Checkpoint Blockade

Checkpoint inhibitors — anti-PD-1 (nivolumab, pembrolizumab), anti-PD-L1 (atezolizumab, durvalumab, avelumab), and anti-CTLA-4 (ipilimumab) — do not directly kill tumor cells. Instead they remove inhibitory signals that tumor cells exploit to silence tumor-infiltrating T lymphocytes. Anti-PD-1/PD-L1 antibodies block the PD-1–PD-L1 axis in the tumor microenvironment, restoring effector CD8+ T-cell activity. Anti-CTLA-4 acts earlier, in the lymph node priming phase, augmenting the initial T-cell response and depleting regulatory T cells via ADCC (Zinn et al., Nat Cancer 2023).

4. Antibody-Drug Conjugates (ADCs)

ADCs link a tumor-targeting mAb to a potent cytotoxic payload via a cleavable or non-cleavable chemical linker. The antibody delivers the drug selectively to antigen-expressing tumor cells; after internalization, the linker is cleaved and the payload — typically a microtubule inhibitor (MMAE, emtansine) or topoisomerase I inhibitor (DXd, SN-38) — is released intracellularly to kill the cell. ADCs combine the targeting precision of a mAb with the killing power of a chemotherapy agent. Ado-trastuzumab emtansine (T-DM1/Kadcyla) and trastuzumab deruxtecan (T-DXd/Enhertu) exemplify this class for HER2-positive breast cancer (Zahavi & Weiner, Antibodies 2020).

5. Bispecific Antibodies

Bispecific antibodies (BsAbs) carry two distinct antigen-binding arms, allowing simultaneous engagement of two targets. The most clinically validated design is the T-cell engager: one arm binds a tumor antigen (e.g., CD19, CD20, BCMA) and the other binds CD3ε on T cells, physically redirecting cytotoxic T cells to kill tumor cells independent of MHC-I presentation. Blinatumomab (CD19×CD3) was the first BsAb approved for a hematological malignancy (B-ALL, 2014). Amivantamab (EGFR×MET) represents the first BsAb approved for a solid tumor (NSCLC, 2021).

Key FDA-Approved Monoclonal Antibodies in Oncology

The FDA has approved antibody-based oncology agents across every major tumor antigen category. Below are the landmark approvals that define cancer monoclonal antibody therapy as it stands today.

Rituximab (anti-CD20) — FDA 1997

Rituximab was the first anti-cancer mAb approved by the FDA. It targets CD20, a cell-surface phosphoprotein on pre-B and mature B cells, and kills malignant B cells through ADCC, CDC, and direct apoptosis induction. Approved indications include CD20-positive non-Hodgkin lymphoma, chronic lymphocytic leukaemia (CLL), follicular lymphoma, and diffuse large B-cell lymphoma (DLBCL). Rituximab transformed DLBCL from a largely incurable disease into one with a cure rate exceeding 60% when combined with CHOP chemotherapy (Coiffier et al., NEJM 2002).

Trastuzumab (anti-HER2) — FDA 1998

Trastuzumab targets the extracellular domain IV of HER2, blocking receptor dimerization and activating ADCC. It is FDA-approved for HER2-positive breast cancer (metastatic and early-stage adjuvant) and HER2-positive gastric or gastroesophageal junction adenocarcinoma. HER2 amplification, defined as a HER2/CEP17 ratio ≥2.0 or HER2 copy number ≥6.0 by FISH, is the companion diagnostic criterion for patient selection.

Bevacizumab (anti-VEGF) — FDA 2004

Bevacizumab neutralizes all VEGF-A isoforms, collapsing tumor neovascularization. FDA-approved indications include metastatic colorectal cancer (first-line), non-squamous NSCLC, recurrent glioblastoma, metastatic renal cell carcinoma, cervical cancer, and platinum-resistant ovarian cancer. It is typically combined with chemotherapy rather than used as a monotherapy.

Cetuximab (anti-EGFR) — FDA 2004

Cetuximab, a chimeric IgG1, blocks EGF and TGF-α binding to EGFR and induces receptor internalization. It is approved for RAS wild-type metastatic colorectal cancer and recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). KRAS/NRAS mutation testing is mandatory before use — tumors with RAS mutations do not respond.

Checkpoint Inhibitors — FDA 2011–2016

Ipilimumab (anti-CTLA-4, 2011) was the first approved checkpoint inhibitor, in unresectable/metastatic melanoma. Nivolumab and pembrolizumab (both anti-PD-1, 2014) followed with broader indications spanning melanoma, NSCLC, HNSCC, classical Hodgkin lymphoma, MSI-H/dMMR tumors across tissue types, and many others. Pembrolizumab achieved the first tumor-agnostic FDA approval in 2017 for any MSI-H/dMMR solid tumor, establishing biomarker-based (rather than histology-based) drug approval. PD-L1 IHC testing (using companion diagnostic clones such as 22C3 for pembrolizumab) and/or MSI/TMB assessment are used for patient stratification.

Antibody-Drug Conjugates — FDA 2013–Present

Ado-trastuzumab emtansine (T-DM1/Kadcyla, FDA 2013) was the first ADC approved for breast cancer, combining trastuzumab with the microtubule inhibitor DM1 via a non-cleavable thioether linker. Trastuzumab deruxtecan (T-DXd/Enhertu, FDA 2019 accelerated) uses a cleavable tetrapeptide linker to deliver the topoisomerase I inhibitor DXd, enabling a bystander killing effect on neighboring antigen-low tumor cells. Sacituzumab govitecan (FDA 2020) targets TROP2 and delivers SN-38 (the active metabolite of irinotecan) to triple-negative breast cancer and urothelial carcinoma. The ADC field has expanded rapidly; as of 2025 there are more than 15 FDA-approved ADCs across oncology indications.

Emerging Trends in Antibody-Based Cancer Therapy

Several structural and engineering innovations are reshaping the antibody drug conjugate and bispecific antibody landscape:

• Next-generation ADCs: Site-specific conjugation (engineered cysteines, unnatural amino acids, enzymatic ligation) produces homogeneous drug-to-antibody ratios (DAR), improving therapeutic index versus stochastic lysine or cysteine conjugation. High-DAR ADCs (DAR 8) and biparatopic ADCs (binding two non-overlapping epitopes on the same antigen) are in clinical development.
• Bispecific T-cell engagers (BiTEs and related formats): Beyond blinatumomab (CD19×CD3), a second generation of off-the-shelf T-cell engagers — mosunetuzumab (CD20×CD3, FDA 2022), teclistamab (BCMA×CD3, FDA 2022), talquetamab (GPRC5D×CD3, FDA 2023) — have reshaped multiple myeloma and follicular lymphoma treatment. These formats approach CAR-T in activity for some hematological settings without the manufacturing complexity or logistical burden of autologous cell therapy.
• Bispecific checkpoint + tumor antigen combinations: Antibodies that simultaneously block PD-L1 and another checkpoint (e.g., TIM-3, LAG-3, TIGIT) or co-stimulate T cells while blocking PD-1 are entering pivotal trials, aiming to overcome single-checkpoint resistance.
• Fc engineering: Afucosylation (e.g., obinutuzumab) boosts FcγRIIIA binding ~50-fold, enhancing ADCC against CD20-positive B-cell malignancies. Half-life extension via FcRn binding optimization (M428L/N434S mutations) enables monthly or quarterly dosing intervals. Subcutaneous formulations using hyaluronidase co-formulation (e.g., subcutaneous rituximab, trastuzumab) reduce infusion time from hours to minutes.
• Combination strategies: mAbs combined with CDK4/6 inhibitors (for HER2+ breast cancer), PARP inhibitors, or anti-VEGF plus anti-PD-L1 (atezolizumab + bevacizumab in hepatocellular carcinoma) are now standard of care, leveraging mechanistic complementarity.

BioHippo Antibody Research Reagents for Oncology Studies

BioHippo supplies validated cancer research antibodies targeting the same antigens that define clinical mAb therapy — HER2/ERBB2, EGFR, CD20, PD-L1, PD-1, TIM-3, TIGIT, and VEGFR2 — for use in Western blot, IHC, IF, and ELISA. These are research-use reagents, not therapeutics, designed to support mechanistic studies, biomarker assays, and preclinical model validation.

Representative products currently available:

• Anti-HER2/ERBB2 Polyclonal Antibody — validated for WB, IHC, ELISA in human, mouse, rat samples.
• Anti-HER2 scFv Recombinant Antibody (SAA2245) — monoclonal, ELISA-validated, human reactivity.
• Anti-PD-L1/CD274 Polyclonal Antibody — validated for WB, IHC, ELISA.
• Anti-TIM-3/HAVCR2 Polyclonal Antibody — tumor immunology, checkpoint research.
• Anti-TIGIT Polyclonal Antibody — next-generation checkpoint target.

Browse the full Oncology Antibody Spotlight collection or the Validated Cancer Antibodies collection (3,500+ products) for the complete lineup.

FAQ: Cancer Monoclonal Antibody Therapy

How do monoclonal antibodies work in cancer treatment?

Cancer monoclonal antibodies destroy tumor cells through four principal mechanisms: antibody-dependent cellular cytotoxicity (ADCC) mediated by NK cells, complement-dependent cytotoxicity (CDC), direct blockade of growth factor receptors (such as HER2 or EGFR) to halt tumor proliferation, and immune checkpoint blockade to reactivate suppressed tumor-infiltrating T lymphocytes. Antibody-drug conjugates (ADCs) add a fifth mechanism — intracellular delivery of a cytotoxic payload to antigen-expressing tumor cells.

What are the types of monoclonal antibodies used for cancer?

There are four main classes: (1) naked mAbs — unmodified antibodies that kill tumor cells directly or block pro-survival signaling (rituximab, trastuzumab, bevacizumab, cetuximab); (2) checkpoint inhibitors — antibodies targeting PD-1, PD-L1, or CTLA-4 to reactivate anti-tumor immunity (nivolumab, pembrolizumab, ipilimumab); (3) antibody-drug conjugates (ADCs) — mAbs carrying cytotoxic payloads (T-DM1/Kadcyla, T-DXd/Enhertu, sacituzumab govitecan); and (4) bispecific antibodies — dual-targeting agents that redirect T cells or block two tumor-promoting pathways simultaneously (blinatumomab, mosunetuzumab, amivantamab).

Are monoclonal antibodies immunotherapy?

The term "immunotherapy" is accurate for some but not all cancer mAbs. Checkpoint inhibitors (anti-PD-1, anti-PD-L1, anti-CTLA-4) and bispecific T-cell engagers are immunotherapy because they work exclusively by activating or redirecting the patient's own immune cells against the tumor. Naked mAbs like trastuzumab or bevacizumab use partly immune-mediated mechanisms (ADCC) but also act independently of T cells; ADCs are primarily cytotoxic agents guided by an antibody. In regulatory and clinical practice, all four classes are grouped under "monoclonal antibody therapy" or "biologic therapy."

What is the difference between a monoclonal antibody and immunotherapy?

Monoclonal antibodies are a specific molecular format (a single-specificity IgG or engineered derivative). Immunotherapy is a broader treatment category encompassing any approach that activates the immune system against cancer — including checkpoint inhibitors, CAR-T cells, cancer vaccines, and cytokine therapy. All checkpoint-inhibitor and T-cell-engager mAbs are immunotherapy; not all mAbs are immunotherapy. The two terms overlap but are not interchangeable.

Which cancers have the most monoclonal antibody treatment options?

Hematologic malignancies — particularly B-cell non-Hodgkin lymphoma, chronic lymphocytic leukaemia, and multiple myeloma — have the most approved mAb options, owing to well-defined lineage antigens (CD20, CD38, BCMA, CD19) accessible to circulating antibodies. HER2-positive breast cancer is the solid-tumor indication with the most approved HER2-directed agents (trastuzumab, pertuzumab, T-DM1, T-DXd, margetuximab). MSI-H/dMMR tumors across any histology are eligible for pembrolizumab regardless of tissue of origin.

What are antibody-drug conjugates (ADCs) in cancer?

Antibody-drug conjugates are mAbs covalently linked to a cytotoxic small-molecule payload via a chemical linker. The antibody binds a tumor-surface antigen and delivers the drug directly to antigen-expressing cells; after endocytosis and lysosomal processing, the linker is cleaved and the payload is released intracellularly to kill the cell. ADCs separate the systemic toxicity of cytotoxic drugs from their antitumor activity. The key design parameters are the target antigen (expression level and tumor selectivity), linker stability, drug-to-antibody ratio (DAR, typically 2–8), and payload potency and mechanism. As of 2025, more than 15 ADCs are FDA-approved across oncology indications.

How do bispecific antibodies differ from standard monoclonal antibodies?

Standard monoclonal antibodies recognize a single antigen. Bispecific antibodies carry two different antigen-binding arms and can engage two targets simultaneously. In oncology, the most impactful use is T-cell engagers: one arm binds a tumor antigen and the other binds CD3ε on T cells, forcing direct T-cell–tumor cell contact and triggering cytotoxic killing without requiring MHC-I presentation or prior T-cell priming. This allows them to activate even exhausted or MHC-I-downregulated tumor microenvironments that evade conventional cytotoxic T-cell recognition.

References

1. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256(5517):495–497.
2. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol. 2005;23(9):1147–1157.
3. Coiffier B, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235–242.
4. Zahavi D, Weiner L. Monoclonal Antibodies in Cancer Therapy. Antibodies (Basel). 2020;9(3):34.
5. Zinn S, et al. Advances in antibody-based therapy in oncology. Nat Cancer. 2023;4(2):165–180.